Key points are not available for this paper at this time.
The trial met its primary objective of noninferiority in AHV and further showed superiority of lonapegsomatropin compared to daily somatropin, with similar safety, in treatment-naïve children with GHD.
Thornton et al. (Sat,) studied this question.